{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:17:01Z","timestamp":1765495021301,"version":"3.48.0"},"reference-count":15,"publisher":"BMJ","issue":"6753","license":[{"start":{"date-parts":[[1990,9,29]],"date-time":"1990-09-29T00:00:00Z","timestamp":654566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1990,9,29]]},"DOI":"10.1136\/bmj.301.6753.668-d","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T15:19:55Z","timestamp":1238685595000},"page":"668.2-669","source":"Crossref","is-referenced-by-count":9,"title":["Dystonic dysphagia associated with fluspirilene."],"prefix":"10.1136","volume":"301","author":[{"given":"M","family":"Stones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Kennie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1990,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.285.6340.463","article-title":"Neuroleptics and abnormal movements","volume":"285","author":"Lader, M.H.","year":"1982","unstructured":"Lader MH. Neuroleptics and abnormal movements. Br Med J 1982;285:463-4.","journal-title":"Br Med J"},{"issue":"1988","key":"ref_2","first-page":"964","article-title":"Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic","volume":"7","author":"Newton-John, H.","unstructured":"Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. Br Med 7 1988;297:964-5.","journal-title":"Br Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/bmj.300.6718.139","article-title":"The dystonias","volume":"300","author":"Marsden, C.D.; Quinn, N.P.","year":"1990","unstructured":"Marsden CD, Quinn NP. The dystonias. Br Med J 1990;300: 139-44.","journal-title":"Br Med J"},{"key":"ref_4","first-page":"182","article-title":"Lupus erythematodes durch captopril","volume":"41","author":"Schmidt, R.E.; Lange, C.","year":"1982","unstructured":"Schmidt RE, Lange C. Lupus erythematodes durch captopril. Z Rheumatol 1982;41:182.","journal-title":"Z Rheumatol"},{"key":"ref_5","first-page":"150","volume":"i:","author":"Brummnelen, P.; Willemze, R.; Ran, W.D.","year":"1980","unstructured":"Brummnelen P, Willemze R, Ran WD, et al. Captopril-associated agranulocytosis. Lancet 1980;i: 150.","journal-title":"Captopril-associated agranulocytosis. Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0140-6736(80)90854-5","article-title":"Captopril associated granulocytopenia in hypertension after renal transplantation","volume":"i:","author":"Elijovisch, F.; Krakoff, L.R.","year":"1980","unstructured":"Elijovisch F, Krakoff LR. Captopril associated granulocytopenia in hypertension after renal transplantation. Lancet 1980;i:927.","journal-title":"Lancet"},{"key":"ref_7","first-page":"314","article-title":"Captopril-associated granulocytopenia in hypertension after renal transplantation","volume":"22","author":"Shindo, K.; Matsuya, F.; Ura, T.","year":"1984","unstructured":"Shindo K, Matsuya F, Ura T, et al. Captopril-associated granulocytopenia in hypertension after renal transplantation. Clin Nephrol 1984;22:314-6.","journal-title":"Clin Nephrol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/00325481.1985.11698908","article-title":"Drug-induced systemic lupus erythematosus: differentiating it from the real thing","volume":"77","author":"Kale, S.A.","year":"1985","unstructured":"Kale SA. Drug-induced systemic lupus erythematosus: differentiating it from the real thing. Postgrad Med 1985;77: 231-42.","journal-title":"Postgrad Med"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00012995-198704000-00001","article-title":"Recent developments in drug-associated systemic lupus erythematosus","volume":"123","author":"Hughes, G.R.V.","year":"1987","unstructured":"Hughes GRV. Recent developments in drug-associated systemic lupus erythematosus. Adverse Drug Reactions Bulletin 1987; 123:460-3.","journal-title":"Adverse Drug Reactions Bulletin"},{"key":"ref_10","first-page":"1358","article-title":"Hypotensive agents, beta-blockers, and druginduced lupus","volume":"284","author":"Hughes, G.R.V.","year":"1982","unstructured":"Hughes GRV. Hypotensive agents, beta-blockers, and druginduced lupus. Br MedJ7 1982;284: 1358-9."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1001\/jama.1987.03400240064025","article-title":"3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors in the treatment of hypercholesterolemiaJ","volume":"258","author":"Hoeg, J.M.; HB, Jr, Brewer","year":"1987","unstructured":"Hoeg JM, Brewer HB Jr. 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors in the treatment of hypercholesterolemiaJ. AMA 1987;258:3532-6.","journal-title":"AMA"},{"key":"ref_12","first-page":"359","article-title":"A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia","volume":"260","author":"Group, III, Lovastatin Study","year":"1988","unstructured":"Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia.J7AMA 1988;260:359-66."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJM198811033191811","article-title":"HMG-CoA reductase inhibitors for hypercholesterolemia","volume":"319","author":"El, Schaefer","year":"1988","unstructured":"Schaefer El. HMG-CoA reductase inhibitors for hypercholesterolemia. N EnglJ Med 1988;319:1222-3.","journal-title":"N EnglJ Med"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00000441-198812000-00010","article-title":"Topics in clinical pharmacology: lovastatin","volume":"2","author":"Sabra, R.","year":"1988","unstructured":"Sabra R. Topics in clinical pharmacology: lovastatin. AmJI Med Sci 1988;2%:426-8.","journal-title":"AmJI Med Sci"},{"article-title":"Side effects of drugs annual 12","author":"Dulces, M.N.","key":"ref_15","unstructured":"Dulces MN, Beeley L, eds. Side effects of drugs annual 12. Amsterdam: Elsevier, 1988:379."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.301.6753.668-d","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.301.6753.668-d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T23:14:10Z","timestamp":1765494850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.301.6753.668-d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,9,29]]},"references-count":15,"journal-issue":{"issue":"6753","published-online":{"date-parts":[[1990,9,29]]},"published-print":{"date-parts":[[1990,9,29]]}},"alternative-id":["10.1136\/bmj.301.6753.668-d"],"URL":"https:\/\/doi.org\/10.1136\/bmj.301.6753.668-d","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1990,9,29]]}}}